A combined phase 1 and 2 study investigating the combination of RAD001 [everolimus] and erlotinib in patients with advanced NSCLC [non-small cell lung cancer] previously treated only with chemotherapy.

Trial Profile

A combined phase 1 and 2 study investigating the combination of RAD001 [everolimus] and erlotinib in patients with advanced NSCLC [non-small cell lung cancer] previously treated only with chemotherapy.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Apr 2015

At a glance

  • Drugs Erlotinib; Everolimus
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Pharmacokinetics; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 23 Dec 2013 Results published in the Annals of Oncology.
    • 29 Jun 2012 Company added in the association field as reported by EudraCT.
    • 02 Apr 2012 Actual end date (March 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top